Skip to main content

Table 1 Clinicopathologic characteristics of miR-29b expression in NSCLC patients

From: MicroRNA-29b attenuates non-small cell lung cancer metastasis by targeting matrix metalloproteinase 2 and PTEN

Features Case(n) Percent -CT P
Age     
>60 14 46.67 −2.044 ± 1.311  
= < 60 16 53.33 −1.807 ± 0.989 0.578
Gender     
Male 16 53.33 −1.883 ± 0.722  
Female 14 46.67 −1.957 ± 1.508 0.862
Histology     
Squamous cancer 4 13.33 −2.182 ± 0.858  
Adenocarcinoma 26 86.67 −1.877 ± 1.182 0.625
Differentiation     
Well + Moderate 21 70 −1.931 ± 1.344  
Poor 9 30 −1.886 ± 0.401 0.891
Clinic Stage     
I 10 33.33 −1.122 ± 0.638  
II 9 30 −1.881 ± 0.453  
III 11 36.67 −2.671 ± 1.398 0.004
Lymphatic Metastasis     
No 16 53.33 −1.505 ± 0.799  
Yes 14 46.67 −2.389 ± 1.302 0.031